Romiplostim

Product Name: Romiplostim

CAS No: 267639-76-9

Purity: 95%

Molar Mass: 59085.01

Chemical Formula: C2634H4086N722O790S18

Synonyms: AMG 531, Nplate, Romiplate

Storage: Store at -20℃

Sequence: MDKTHTCPPC PAPELLGGPS VFLFPPKPKD TLMISRTPEV TCVVVDVSHEDPEVKFNWYV DGVEVHNAKT KPREEQYNST YRVVSVLTVL HQDWLNGKEYKCKVSNKALP APIEKTISKA KGQPREPQVY TLPPSRDELT KNQVSLTCLVKGFYPSDIAV EWESNGQPEN NYKTTPPVLD SDGSFFLYSK LTVDKSRWQQGNVFSCSVMH EALHNHYTQK SLSLSPGKGG GGGIEGPTLR QWLAARAGGGGGGGGIEGPT LRQWLAARA

Target: acute radiation syndrome

Application: Romiplostim (CAS: 267639-76-9) is a pharmaceutical agent with crucial applications in the management of immune thrombocytopenia. As a thrombopoietin receptor agonist, romiplostim stimulates the production and maturation of platelets, addressing the underlying cause of thrombocytopenia. By mimicking the action of endogenous thrombopoietin, romiplostim promotes megakaryocyte proliferation and platelet release, effectively increasing platelet counts in individuals with chronic immune thrombocytopenia. This targeted approach offers a valuable alternative for patients who are unresponsive to conventional therapies. Romiplostim’s mechanism of action exemplifies a strategic intervention in the pharmaceutical landscape, providing a tailored solution to restore platelet levels and mitigate the risk of bleeding complications in individuals facing immune thrombocytopenia challenges.

Reference:

Hashemzaei, M., Ghoshoon, M. B., Jamshidi, M., Moradbeygi, F., Hashemzehi, A., & Ghoshoon, M. B. (2024). A Review on Romiplostim Mechanism of Action and the Expressive Approach in E. coli. Recent Patents on Biotechnology, 18(2), 95-109.

Makarenko, I., Dorotenko, A., Noskov, S., Banko, V., Saparova, V., Khokhlov, A., … & Drai, R. (2023). A randomized, double‐blind, comparative study of the pharmacodynamics and pharmacokinetics of GP40141 (romiplostim biosimilar) and reference romiplostim in healthy male volunteers. Pharmacology Research & Perspectives, 11(5), e01125.